Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Comment by subaru1ion Nov 16, 2023 2:00pm
136 Views
Post# 35739662

RE:M&A

RE:M&AGood point, but "M&A activity" is a 2 way street the first you are merging start source or the acquisition start source.  The other side of the street, you merge with someone bigger or are acquired by someone bigger.   Why do you think Virtu ITG is working retail shareholders with multiple accounts, to make 1/2 a cent per share?  They are shaking the retail tree as hard as possible to see how many less informed shareholders they can shake out of their shares.    It's all about making as much money as possible and that is what their activity should be telling you.   

The key to a lot of this is which company licensed EPM patents to produce or have produced for them the acid form of cannabinoids.  Is it LABS or their global pharma partner?  I have a tendency to lean towards the global pharma partner holding those licenses and LABS, as a certified cannabinoid pharma facility produces the product.   That makes sense to me and why a global pharma is partnered with LABS while 'for competitive reasons' holds things in secrecy.  

Bourla, CEO of Pfizer, interestingly enough attended the Xi-Biden event because Pfizer does have a deal with China to improve health care for China and interestingly enough China is doing advanced cannabinoid research on advanced derivatives including the acid forms.   That I could easily say, has a Pfizer touch IF Pfizer has the patents on acid stabilization form.  

I could also say that China is doing that development work because they've kicked with economic sanctions and restrictions by the regime that thinks they run everything on this Planet.   A rude awakening is unfolding right before your very eyes, a cliche, history in the making, just like the collapse of the Roman empire that wanted to rule everything as well.  History does repeat itself and so too not a recession but the real risk of a depression in North America.  
<< Previous
Bullboard Posts
Next >>